A Part of the University of Maryland Medical Center

Connect with UMGCC
Facebook Twitter YouTube Blog iPhone
Email PageEmail page Print PagePrint page

Research: Shared Services

Translational Laboratory

Articles in Peer Reviewed Journals

  1. Xie M, Ujjinamatada RK, Sadowska M, Lapidus RG, Edelman M and Hosmane RS. A novel, broad spectrum anti-cancer compound containing the Imidazo[4,5-e][1,3]diazepine Ring System.  Bioorganic and Medicinal Chemistry Letters 20(15):4386-9 2010

  2. Kondaskar A, Kondaskar S, Kumar R, Muvarak N, Lapidus RG, Sadowska M, Edelman MJ, Bol GM, Raman V and Hosmane RS  A Series of Novel, Broad Spectrum Anti-Cancer AgentsContaining the Tricyclic 5:7:5-Fused Diimidazodiazepine Ring System  ACS Med Chem Letters  2(3):  252-256, 2010.

  3. Lee TY, Ezelle HJ, Venkataraman T, Lapidus RG, Scheibner K, Hassel BA: Regulation of human RNase L by the miR-29 family reveals a novel oncogenic role in chronic myelogenous leukemia  J Interferon and Cytokine Res  33(1): 34-42, 2013

  4. Kondaskar A, Kondaskar S, Fishbein JC, Carter-Cooper, BA, Lapidus RG, Sadowska M, Edelman MJ and Hosmane RS.  Structure-based drug design and potent anti-cancer activity of tricyclic 5:7:5-fused diimidazo[4,5-d:4’5’-f][1,3]diazepines.  Biorg Med Chem 21(3): 618-631, 2013

  5. Zimmer DB, Lapidus RG, Weber DJ. In vivo screening of S100B inhibitors for melanoma therapy Methods Mol Biol. 963:303-17, 2013.

  6. Gojo I, Tan M, Fang H-B, Sadowska M, Lapidus R, Baer MR, Carrier F, Beumer JH, Anyang BN, Holleran JL, Srivastava RK, Espinoza-Delgado I, Ross DD. Translational phase I trial of vorinostat combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia  Clin Cancer Res 19(7):1838-1851 2013

  7. Guha P, Kaptan E, Bandyopadhyaya, Kaczanowska S, Davila E, Thompson K, Martin SS, Kalvakolanu DV, Vasta GR and Ahmed H.  Cod glycopeptide with picomolar affinity to galectin-3 suppresses T-cell apoptosis and prostate cancer metastasis PNAS 110(13):5052-72013 ; 10

Abstracts Presented at National Meetings

  1. Sadowska M, Muvarak N, Lapidus RG, Sausville E, Derosier M, Bannerji R, Gojo I.  Single Agent Activity of Cyclin Dependent Kinase (CDK) Inhibtor Dinaciclib (SCH 727965) in Acute Myeloid and Lymphoid Leukemia Cells  Annual Meetings Proceedings ASH 2010

  2. Hung C,  Kuo Y, Choi E, Raghavan S, Mistry N, Gullapalli R, Lapidus RG, Suntharalingam M, D'souza WD.  Theranostic Nanoprobes for Targeting and Imaging of the Epidermal Growth Factor Receptor International Journal of Radiation Oncology Biology Physics. 2011, 81(2):S143-S144
       
  3. Badros A, Philip S, Lesho P, Weikle D, Goloubeva O, Sadowska M, Lapidus R, Silbaugh L, Hester L, Milliron T, and Meiller T.  Prospective observational study of 110 multiple myeloma (MM) patients on monthly versus 3 monthly infusion of zoledronic acid.  ASH Proceeding 2012

  4. Bao T,  Porter N, Primrose J, Goloubeva O, Hester L, Wang L, Sadowska M, Lapidus R, Medeiros M, Lao L, Dorsey S, and Badros AZ.   A Pilot Study of Acupuncture in Treating Bortezomib-Induced Peripheral Neuropathy (BIPN) in Multiple Myeloma (MM) Patients.  ASH Proceeding 2012

  5. Emadi A, Sadowska M, Cooper BC, Lapidus RG, Sausville E   Synergistic effect of combining arsenic trioxide (ATO)and dichloroacetate (DCA) in acute myelogenous leukemia cells.  Proceeding of AACR 2013

  6. Edelman MJ, Feliciano JL, Styblo M, Liu T and Lapidus RG.  Phase I and pharmacokinetic trial of the antitelomerase agent KML001 (KML) and cisplatin (CDDP) in advanced solid tumors.  Proceedings of ASCO 2013.

This page was last updated on: June 28, 2013.